Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.77 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.77 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.77 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.72 |
| ▸ | MAOB | P27338 | 1/20 | 0.72 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.70 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.63 |
| ▸ | PTPRC | P08575 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.61 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6830467 | 0.87 | NR4A2 (1.00) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL4059143 | 0.87 | NR4A2 (1.00) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL3232949 | 0.87 | SRD5A2 (0.90) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL228477 | 0.87 | NR4A2 (1.00) | NR4A1NR4A2NR4A3PARP10MAOB | |
| Hydrochloric Acid SCHEMBL8544438 | 0.85 | NR4A2 (0.96) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL11603952 | 0.85 | NR4A2 (0.96) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL11603274 | 0.85 | NR4A2 (0.96) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL11273693 | 0.85 | NR4A2 (0.96) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL402300 | 0.85 | SRD5A2 (0.87) | NR4A1NR4A2NR4A3PARP10MAOB | |
| SCHEMBL228290 | 0.84 | NR4A2 (0.74) | NR4A1NR4A2NR4A3PARP10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091228-A1 | Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary Dysfunction | TOSK, INC. | 2024-03-21 | — | — | US | disclosed |
| CN-117597139-A | Uridine phosphorylase inhibitors for preventing or treating drug-induced pulmonary dysfunction | 托斯克公司 | 2024-02-23 | — | — | CN | disclosed |
| EP-4301398-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO PREVENT OR TREAT DRUG-INDUCED PULMONARY DYSFUNCTION | Tosk, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-20230255971-A1 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions | TOSK, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-4178581-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO TREAT OR PREVENT PULMONARY DISEASE | Tosk, Inc. (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-116096422-A | Uridine phosphorylase inhibitors for treating or preventing pulmonary diseases | 托斯克公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-114450009-A | Uridine Phosphorylase (UPASE) inhibitors for the treatment of liver diseases | 托斯克公司 | 2022-05-06 | — | — | CN | disclosed |
| EP-3986409-A1 | URIDINE PHOSPHORYLASE (UPASE) INHIBITORS FOR TREATMENT OF LIVER CONDITIONS | Tosk, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022010778-A1 | URIDINE PHOSPHORYLASE INHIBITORS TO TREAT OR PREVENT PULMONARY DISEASE | TOSK, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-20220008422-A1 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | TOSK, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-2265274-B1 | METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK INC (US) | 2018-11-21 | — | — | EP | disclosed |
| CN-104667279-B | Methotrexate adjuvants to reduce toxicity and methods of use thereof | 托斯克公司 | 2018-10-26 | — | — | CN | disclosed |
| US-9382287-B2 | Methotrexate adjuvants to reduce toxicity and methods for using the same | TOSK, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150072945-A1 | Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same | TOSK, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8853227-B2 | Methotrexate adjuvants to reduce toxicity and methods for using the same | TOSK, INCORPORATED (US) | 2014-10-07 | — | — | US | disclosed |
| US-20110319419-A1 | Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same | TOSK, INCORPORATED | 2011-12-29 | — | — | US | disclosed |
| US-7998967-B2 | Methotrexate adjuvants to reduce toxicity and methods for using the same | TOSK, INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2265274-A2 | METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20090325969-A1 | METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| WO-2009114325-A2 | METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319419-A1 | Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same | TYMP, MTAP, PNP | NR4A1 4666/4885NR4A2 4522/4885NR4A3 4564/4885 |
| US-20150072945-A1 | Methotrexate Adjuvants to Reduce Toxicity and Methods for Using the Same | TYMP, MTAP, PNP | NR4A1 4666/4885NR4A2 4522/4885NR4A3 4564/4885 |
| US-20090325969-A1 | METHOTREXATE ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TYMP, MTAP, PNP | NR4A1 4666/4885NR4A2 4522/4885NR4A3 4564/4885 |
| US-20220008422-A1 | Uridine Phosphorylase Inhibitors to Treat or Prevent Pulmonary Disease | UPP1, UMPS, PNP | NR4A1 4419/4885NR4A2 4268/4885NR4A3 3948/4885 |
| US-20230255971-A1 | Uridine Phosphorylase (UPase) Inhibitors for Treatment of Liver Conditions | UMPS, UPP1, PNP | NR4A1 2828/4885NR4A2 2598/4885NR4A3 2239/4885 |
| US-20240091228-A1 | Uridine Phosphorylase Inhibitors to Prevent or Treat Drug-Induced Pulmonary Dysfunction | UMPS, UPP1, PNP | NR4A1 4642/4885NR4A2 4668/4885NR4A3 4377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.